Exenatide treatment may reduce CVD risk in Type 2 diabetes patients
MedWire News: Treatment with exenatide reduces the risk for cardiovascular disease (CVD)-related events in patients with Type 2 diabetes, compared with treatment with other hypoglycemic therapies, report US researchers.
Jennie Best (Amylin Pharmaceuticals, San Diego, California) and colleagues used data from the LifeLink medical insurance claims database to assess whether treatment of Type 2 diabetes with twice-daily exenatide injections leads to reduced CVD event rates compared with other antidiabetic medications.
They found that Type 2 diabetics treated with exenatide (n=39,275) were a significant 19% less likely to have a CVD event (myocardial infarction, ischemic stroke, coronary revascularization) than Type 2 diabetics treated with other medications (n=381,218).
In addition, diabetic patients treated with exenatide were a significant 12% and 6% less likely to require CVD-related or all-cause hospitalization, respectively, than those on other therapies.
Of note, lipid levels, blood pressure, obesity, and prior CVD rates were higher in patients treated with exenatide than those treated with other antihyperglycemic drugs, lending further support to the results.
"In a 'real world' cohort of patients with Type 2 diabetes, use of exenatide twice daily was associated with a reduced risk for CVD events and CVD-related hospitalization," say Best et al.
The team cautions that the results do not "address potential questions about whether nonexenatide agents may be associated with increased risk (with possible absence of benefit from exenatide) or neutral risk of CVD events."
They suggest: "The improved CV outcomes observed in this retrospective database analysis need to be confirmed in prospective studies of treatment with exenatide."
The results of this study are published in the journal Diabetes Care.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2011
By Helen Albert